Literature DB >> 18832004

Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.

Anasuya Chattopadhyay1, Steven Park, Guillaume Delmas, Rema Suresh, Svetlana Senina, David S Perlin, John K Rose.   

Abstract

We have developed an experimental recombinant vesicular stomatitis virus (VSV) vectored plague vaccine expressing a secreted form of Yersinia pestis low calcium response protein V (LcrV) from the first position of the VSV genome. This vector, given intramuscularly in a single dose, induced high-level antibody titers to LcrV and gave 90-100% protection against pneumonic plague challenge in mice. This single-dose protection was significantly better than that generated by VSV expressing the non-secreted LcrV protein. Increased protection correlated with increased anti-LcrV antibody and a bias toward IgG2a and away from IgG1 isotypes. We also found that the depletion of CD4+ cells, but not CD8+ cells, at the time of challenge resulted in reduced vaccine protection, indicating a role for cellular immunity in protection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832004      PMCID: PMC2628553          DOI: 10.1016/j.vaccine.2008.09.031

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  61 in total

1.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

2.  A single dose sub-unit vaccine protects against pneumonic plague.

Authors:  E D Williamson; S M Eley; A J Stagg; M Green; P Russell; R W Titball
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

3.  Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection.

Authors:  Alexander V Philipovskiy; Stephen T Smiley
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

4.  Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies.

Authors:  B Schlereth; J K Rose; L Buonocore; V ter Meulen; S Niewiesk
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 5.  Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Authors:  T V Inglesby; D T Dennis; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; J F Koerner; M Layton; J McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; M Schoch-Spana; K Tonat
Journal:  JAMA       Date:  2000-05-03       Impact factor: 56.272

6.  Development of in vitro correlate assays of immunity to infection with Yersinia pestis.

Authors:  J Bashaw; S Norris; S Weeks; S Trevino; J J Adamovicz; S Welkos
Journal:  Clin Vaccine Immunol       Date:  2007-03-21

7.  Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy.

Authors:  J E Eyles; E D Williamson; I D Spiers; H O Alpar
Journal:  Vaccine       Date:  2000-08-01       Impact factor: 3.641

8.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 9.  Current challenges in the development of vaccines for pneumonic plague.

Authors:  Stephen T Smiley
Journal:  Expert Rev Vaccines       Date:  2008-03       Impact factor: 5.217

10.  Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells.

Authors:  Yoonkyung Do; Chae Gyu Park; Young-Sun Kang; Sung Ho Park; Rebecca M Lynch; Haekyung Lee; Bradford S Powell; Ralph M Steinman
Journal:  Eur J Immunol       Date:  2008-01       Impact factor: 5.532

View more
  20 in total

1.  Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody.

Authors:  John B Schell; Kapil Bahl; Nina F Rose; Linda Buonocore; Meredith Hunter; Preston A Marx; Celia C LaBranche; David C Montefiori; John K Rose
Journal:  Vaccine       Date:  2012-04-23       Impact factor: 3.641

2.  Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.

Authors:  Devender Kumar; Girish Kirimanjeswara; Dennis W Metzger
Journal:  Clin Vaccine Immunol       Date:  2011-08-31

Review 3.  Developing live vaccines against plague.

Authors:  Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  J Infect Dev Ctries       Date:  2011-09-14       Impact factor: 0.968

4.  Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.

Authors:  Anthony N van den Pol; Guochao Mao; Anasuya Chattopadhyay; John K Rose; John N Davis
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

Review 5.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

6.  The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Authors:  Melissa A Cobleigh; Clinton Bradfield; Yuanjie Liu; Anand Mehta; Michael D Robek
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

7.  Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach.

Authors:  Anasuya Chattopadhyay; John K Rose
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

8.  Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.

Authors:  Anthony J Hickey; Jr-Shiuan Lin; Lawrence W Kummer; Frank M Szaba; Debra K Duso; Michael Tighe; Michelle A Parent; Stephen T Smiley
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

9.  A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.

Authors:  Anasuya Chattopadhyay; Eryu Wang; Robert Seymour; Scott C Weaver; John K Rose
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

10.  D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague.

Authors:  Frank M Szaba; Lawrence W Kummer; Lindsey B Wilhelm; Jr-Shiuan Lin; Michelle A Parent; Sara W Montminy-Paquette; Egil Lien; Lawrence L Johnson; Stephen T Smiley
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.